Century Therapeutics (IPSC) Share-based Compensation (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Share-based Compensation of $6.5 million for Q1 2026, up 169.58% year-over-year from $2.4 million in Q1 2025, and up 403.08% quarter-over-quarter from $1.3 million in Q4 2025.
Century Therapeutics (IPSC) Share-based Compensation (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Share-based Compensation for 7 consecutive years, with $6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 169.58% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (down 45.07% YoY), while the FY2025 annual figure was $6.8 million, down 46.09% from the prior year.
- Share-based Compensation advanced to $6.5 million in Q1 2026 per IPSC's latest filing, from $1.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.5 million in Q1 2026 and bottomed at $1.3 million in Q4 2025.
- Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $3.0 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 2405.26% — and 2025, when it sank 51.13%.
- Century Therapeutics' Share-based Compensation stood at $2.7 million in 2022, then soared by 30.38% to $3.6 million in 2023, then fell by 25.32% to $2.7 million in 2024, then tumbled by 51.13% to $1.3 million in 2025, then jumped by 403.08% to $6.5 million in 2026.
- Business Quant data shows IPSC's Share-based Compensation at $6.5 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Mn |
| Jun 30, 2026 | 1.95 Mn |
| Mar 31, 2026 | 6.54 Mn |
| Mar 31, 2026 | 6.54 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Jun 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 2.22 Mn |
| Mar 31, 2025 | 2.43 Mn |
| Mar 31, 2025 | 2.43 Mn |
| Dec 31, 2024 | 2.66 Mn |
| Dec 31, 2024 | 2.66 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 3.21 Mn |
| Mar 31, 2024 | 3.21 Mn |
| Dec 31, 2023 | 3.56 Mn |
| Dec 31, 2023 | 3.56 Mn |